ACM
STRO icon

ADAR1 Capital Management’s Sutro Biopharma STRO Stock Holding History

ADAR1 Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Buy
524,441
+457,364
+682% +$8.27M 0.77% 31
2025
Q4 		$776K Buy
+67,077
New +$637K 0.06% 155

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ADAR1 Capital Management's STRO Position: Q1 2026 in Review

ADAR1 Capital Management increased its Sutro Biopharma (STRO) stake by 682% in Q1 2026, buying an estimated $8.27M and bringing the position to 524,441 shares worth $13.1M. The position accounts for 0.77% of the portfolio, ranked #31.

ADAR1 Capital Management first reported a position in STRO in Q4 2025 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • ADAR1 Capital Management held 524,441 shares of Sutro Biopharma worth $13.1M as of Q1 2026.
  • ADAR1 Capital Management bought 457,364 Sutro Biopharma shares in Q1 2026, an estimated $8.27M.
  • Sutro Biopharma made up 0.77% of ADAR1 Capital Management's portfolio in Q1 2026, its #31 holding.
  • ADAR1 Capital Management first reported a position in Sutro Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.